Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increased Th17 activation and gut microbiota diversity are associated with pembrolizumab-triggered tuberculosis
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-08-06
DOI
10.1007/s00262-020-02687-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy
- (2020) Ya‐Ru Miao et al. Advanced Science
- Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients With Cancer—Reply
- (2020) David J. Pinato et al. JAMA Oncology
- Induction of peripheral effector CD8 T cell proliferation by combination of paclitaxel, carboplatin and bevacizumab in non-small cell lung cancer patients
- (2019) Pauline L de Goeje et al. CLINICAL CANCER RESEARCH
- Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis
- (2019) Prabhakaran Kumar et al. SEMINARS IN CANCER BIOLOGY
- The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
- (2019) Yongfei Hu et al. Frontiers in Cellular and Infection Microbiology
- Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review
- (2019) Ronwyn van Eeden et al. Frontiers in Oncology
- Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations
- (2019) Amalia Anastasopoulou et al. Journal for ImmunoTherapy of Cancer
- Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab
- (2019) Oscar Blanch-Lombarte et al. Journal of Clinical Medicine
- Pembrolizumab Interferes with the Differentiation of Human FOXP3+–Induced T Regulatory Cells, but Not with FOXP3 Stability, through Activation of mTOR
- (2019) Varun Sasidharan Nair et al. JOURNAL OF IMMUNOLOGY
- Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer
- (2018) Kristian Hastoft Jensen et al. ACTA ONCOLOGICA
- Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non–Small Cell Lung Cancer
- (2018) Nicholas M. Mark et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment
- (2018) H. Picchi et al. CLINICAL MICROBIOLOGY AND INFECTION
- Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction
- (2018) Kei Kunimasa et al. INVESTIGATIONAL NEW DRUGS
- Stromal PD-L1–Positive Regulatory T cells and PD-1–Positive CD8-Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy
- (2018) Si-Pei Wu et al. Journal of Thoracic Oncology
- Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition
- (2018) Paul T Elkington et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs
- (2018) Yongfeng Hu et al. JOURNAL OF INFECTION
- Activated pulmonary tuberculosis in a patient with melanoma during PD-1 inhibition: a case report
- (2018) Wan He et al. OncoTargets and Therapy
- Pericardial Tamponade Caused by a Hypersensitivity Response to Tuberculosis Reactivation after Anti–PD-1 Treatment in a Patient with Advanced Pulmonary Adenocarcinoma
- (2017) Yi-Chun Chu et al. Journal of Thoracic Oncology
- Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis
- (2017) L Majlessi et al. Mucosal Immunology
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Anti-PD1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis
- (2016) Kohei Fujita et al. Journal of Thoracic Oncology
- Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype
- (2016) Leopoldo N. Segal et al. Nature Microbiology
- Psoriasis as a manifestation of HIV-related immune reconstitution inflammatory syndrome
- (2015) Shivani V. Tripathi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge
- (2015) L Monin et al. Mucosal Immunology
- B Cells and Programmed Death-Ligand 2 Signaling Are Required for Maximal Interferon-γ Recall Response by Splenic CD4+ Memory T Cells of Mice Vaccinated with Mycobacterium tuberculosis Ag85B
- (2015) Antonella Riccomi et al. PLoS One
- Programmed death-1 receptor suppresses γ-IFN producing NKT cells in human tuberculosis
- (2014) Amar Singh et al. TUBERCULOSIS
- Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
- (2009) Shinji Kagami et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started